Vigabatrin is a medication used to treat epilepsy. It became available as a generic medication in 2019. It works by inhibiting the breakdown of γ-aminobutyric acid. It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.